1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cardiovascular Disease Related Products (723):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13948
    Angiotensin II human 4474-91-3 99.34%
    Angiotensin II human is converted by Angiotensin I through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE). Angiotensin II is mediated by AT1 and AT2 receptors, which are seven transmembrane glycoproteins with 30% sequence similarity.
    Angiotensin II human
  • HY-A0190
    Ceruletide 17650-98-5 99.96%
    Ceruletide, a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, is a potent cholecystokinetic agent; also activates NF-kappaB/Rel in vitro.
    Ceruletide
  • HY-13441
    (-)-Blebbistatin 856925-71-8 99.47%
    (-)-Blebbistatin is an S enantiomer of blebbistatin. Blebbistatin is a potent and selective myosin II inhibitor with IC50 values ranging from 0.5 to 5 μM.
    (-)-Blebbistatin
  • HY-B0468
    Isoprenaline hydrochloride 51-30-9 99.97%
    Isoprenaline (hydrochloride) is a non-selective beta-adrenergic receptor agonist, used for the treatment of bradycardia and heart block.
    Isoprenaline hydrochloride
  • HY-12298
    GKT137831 1218942-37-0 99.43%
    GKT137831 is a novel, specific dual NADPH oxidase (NOX1/4) inhibitor. GKT137831 has potency both on human Nox4 (Ki=140±40 nM) and human Nox1 (Ki=110±30 nM) and is found 15-fold less potent on Nox2 (Ki=1750±700 nM) and 3-fold less potent on Nox5 (Ki=410±100 nM).
    GKT137831
  • HY-N0504
    Lovastatin 75330-75-5 99.47%
    Lovastatin, a HMG-CoA reductase inhibitor, is a cholesterol-lowering drug.
    Lovastatin
  • HY-19363
    GW4869 6823-69-4
    GW4869 is a noncompetitive neutral sphingomyelinase inhibitor with an IC50 of 1 μM.
    GW4869
  • HY-17502
    Simvastatin 79902-63-9 >98.0%
    Simvastatin is a competitive inhibitor of HMG-CoA reductase with Kd of 0.1-0.2 nM.
    Simvastatin
  • HY-A0064
    Verapamil hydrochloride 152-11-4 99.97%
    Verapamil hydrochloride is an L-type calcium channel antagonist.
    Verapamil hydrochloride
  • HY-17512A
    Losartan potassium 124750-99-8 99.91%
    Losartan (potassium) is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
    Losartan potassium
  • HY-P0017
    Aprotinin 9087-70-1 99.56%
    Aprotinin is a serine protease inhibitor isolated from bovine lung which inhibits trypsin and chymotrypsin with Ki values of 0.06 pM and 9 nM, respectively.
    Aprotinin
  • HY-17365
    Octreotide acetate 79517-01-4 99.78%
    Octreotide (acetate) is a long-acting octapeptide and somatostatin analog with pharmacologic actions mimicking those of the natural hormone somatostatin.
    Octreotide acetate
  • HY-17379
    Atorvastatin hemicalcium salt 134523-03-8 99.13%
    Atorvastatin (hemicalcium salt) is a potent HMG-CoA reductase inhibitor with the IC50 value of 8 nM.
    Atorvastatin hemicalcium salt
  • HY-13715B
    Norepinephrine bitartrate monohydrate 108341-18-0 99.75%
    Norepinephrine bitartrate monohydrate is a β1-selective adrenergic receptor agonist with EC50 of 5.37 μM.
    Norepinephrine bitartrate monohydrate
  • HY-B0284
    Nifedipine 21829-25-4
    Nifedipine is a potent calcium channel blocker and drug of choice for cardiac insufficiencies.
    Nifedipine
  • HY-50903
    Rivaroxaban 366789-02-8 99.96%
    Rivaroxaban is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    Rivaroxaban
  • HY-15778
    AVE 0991 304462-19-9 99.16%
    AVE 0991 is a nonpeptide and orally active Ang-(1-7) agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21±35 nM.
    AVE 0991
  • HY-101952
    Prostaglandin E2 363-24-6 >98.0%
    Prostaglandin E2 is a vasodilator isolated from prostate gland secretion, working by binding and activating the prostaglandin E2 receptor.
    Prostaglandin E2
  • HY-10627A
    GW3965 hydrochloride 405911-17-3
    GW3965 hydrochloride is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively.
    GW3965 hydrochloride
  • HY-14184
    Macitentan 441798-33-0 99.30%
    Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan